About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Ocugen

< Previous 1 2 3 4 5 Next >
News headline image
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Provides Business Update with Certain Financials for the Year Ending 2023
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Present at Investing in Cures Summit
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Clinical Showcase Webcast Now Available
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Present at 2024 BIO CEO & Investor Conference
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Present at Pharma Market Research Conference
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Provides Business Update with Third Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
From Ocugen
Via GlobeNewswire
Tickers OCGN
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.